Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx Inc.

Ardelyx ( ($ARDX) ) has provided an announcement. On April 16, 2026, Ardelyx’s board approved a second amendment to its Amended and Restated 2014 E...

Ardelyx Shareholders Approve Equity Plan Amendment and Directors

Ardelyx Inc ($ARDX) announced an update on their ongoing clinical study. This Phase 3 study, titled “A 26-Week, Multi-Center, Randomized, Double-Bl...

Market Cap	$1.40B	P/E Ratio	N/A
52W High	$8.40	52W Low	$3.49
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	14.8%	52W Position	52.1%
Overall Score	50	Value Score	40
Quality Score	39	Technical Score	72

EPS Current Est	$-0.07	EPS Next Est	$0.53
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARDX	$6.05	+3.60%	9.84M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARDX	$6.05	+3.6%	9.84M
3
4
5
6

ARDX

ARDX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Ardelyx Inc. Data in Excel

Get Ardelyx Inc. Data in Excel